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551Is Viability Imaging Still Relevant in 2012?
W I T H T H E P U B L I C A T I O N O F T H E S T I C H (Surgical Treatment for Ischemic
eart Failure) trial (1) and the viability substudy (2), questions have arisen regarding the utility of
viability testing in patients with left ventricular systolic dysfunction and coronary artery disease (CAD)
prior to revascularization decisions. Prior observational studies and meta-analyses (3) had suggested
that those with viability demonstrated on noninvasive testing fared better with revascularization,whereas those without might fare worse.
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fIn this issue of iJACC, we present 2
opposing takes on the literature in a
timely and topical iForum. The first
rom Drs. Chareonthaitawee and
ersh presents the pro side, that vi-
ability testing remains relevant in
2012. The second from Dr. Panza
concludes the contrary. It is intriguing
that both sets of authors reflect on
the same literature and come to dif-
ferent conclusions. Both sides discuss
the PARR-2 (PET and Recovery
Following Revascularization Phase 2)
study (4), the first truly randomized
controlled trial of viability testing in
this patient population. Unfortunately,
the clinicians who enrolled patients in
this particular trial did not always fol-
low the recommendations of the posi-
tron emission tomography (PET)
findings, leaving the interpretation of
the study fairly flexible and pointing
out the difficulty of pulling off a study
with such a complex design. Drs.
Chareonthaitawee and Gersh argue
that PARR-2 supports the utility of
viability testing. Dr. Panza, on the
other hand, suggests that the clini-
cians’ bias regarding their patients and
potential benefit overwhelmed the
utility of the PET results with which
they were presented.
Similarly, the 2 groups of investiga-
tors have an opposing take on the
STICH viability results. Drs. Chare-
onthaitawee and Gersh point out that
the multiple limitations of this study
make its results difficult to generalize. vThese limitations include that: 1) it
was a substudy; 2) the use of viability
testing was not randomized nor the
results blinded; 3) there were differ-
ences in baseline characteristics of the
patient groups; and 4) the nonviable
group was relatively small. They state
that this study does not definitively
answer the question regarding the use
of viability testing for decision making.
Dr. Panza, on the other hand, suggests
that in the absence of randomized con-
trolled evidence in favor of viability
testing, it is difficult to justify its use in
the present environment.
The bottom line is that controversy
lingers and this underlies our interest
at iJACC to present this to our read-
ers. Clearly, there is room for further
investigation in this arena to defini-
tively answer this important question
in clinical cardiovascular medicine.
Viability Testing Remains
Relevant in Ischemic Left
Ventricular Dysfunction
Panithaya Chareonthaitawee, MD
Bernard J. Gersh, MB, ChB, DPhil
RATIONALE FOR VIABILITY TESTING
BASED ON OBSERVATIONAL STUDIES.
DESPITE ADVANCES IN THERAPY, the
morbidity and mortality of moderate-to-
severe ischemic left ventricular (LV) sys-
tolic dysfunction remain high (5). In the
bsence of angina, the relative value of re-
ascularization over medical therapy has ieen a source of controversy. Nonran-
omized studies performed over 2 de-
ades ago suggested that using coro-
ary artery bypass graft (CABG) in
oderate-to-severe ischemic LV systolic
ysfunction may lead to prognostic ben-
fit, but the results were offset by limi-
ations in study design and the high
eriprocedural risks prevalent at that
ime (6). Uncertainty regarding the op-
imal treatment strategy in these pa-
ients has, therefore, provided the ratio-
ale for viability testing.
The concepts of myocardial viabil-
ty and viability testing are logical and
echanistically sound (6). Reasonable,
hough nondefinitive, evidence from
ver 100 nonrandomized studies of
ore than 3,000 patients with viabil-
ty testing in the last 2 decades has
onsistently demonstrated its useful-
ess (6–8). In a meta-analysis of pa-
ients with ischemic LV systolic dys-
unction, medically treated patients
ith viability had the highest mortal-
ty rate among the subgroups (Fig. 1)
3). Furthermore, in the presence of vi-
bility, the relative reduction in death
ith revascularization compared with
edical therapy was nearly 80%, with a
1% relative reduction in all other
vents (Fig. 1) (3). Other studies have
emonstrated similar findings, along
ith the ability of viability testing to
redict improvements in regional
nd global LV systolic function, and
unctional capacity after revascular-
zation (6,8).
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552These key observational findings have
culminated in a class IIa recommenda-
tion for viability testing in the Ameri-
can College of Cardiology/American
Heart Association practice guidelines
(5,9) and support the use of viability
testing in moderate-to-severe ischemic
LV systolic dysfunction.
Recent trials of viability testing—steps in
the right direction. PARR-2. Thus far,
the major limitation of the viability
literature is the lack of randomized
controlled trials (RCT) of viability test-
ing. This was addressed partly by the
PARR-2 trial, a noteworthy, and the
largest to date, RCT of PET viability
testing (4). PARR-2 stratified patients
with severe LV systolic dysfunction
(presumed ischemic) to recent angiog-
raphy or not, then randomized to
PET-guided management (n  218)
versus standard care without PET
(where an alternative test could be con-
sidered [n 212]). At 1 year, PARR-2
demonstrated no significant difference
in the composite primary outcome of
cardiac death, myocardial infarction
(MI), or recurrent hospitalization be-
tween the 2 arms.
Although well-conducted, PARR-2
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Figure 1. Death Rates for Patients With and Wit
Revascularization or Medical Therapy
In the presence of viability, a 79.6% reduction in m
cal therapy. Without myocardial viability, there was
2 treatment groups. Adapted, with permission, fromhad lower adherence to PET-guidedrecommendations, which may have re-
duced the ability to detect a difference
in the primary outcome. When only
patients adhering to PET-guided rec-
ommendations were included, the PET
adherence group had significantly bet-
ter outcome than the standard care
group did (adjusted hazard ratio: 0.62).
Furthermore, 39% of patients in the
PET arm and about two-thirds of pa-
tients in the standard arm had at least 1
other form of functional testing within
3 months before or after randomiza-
tion, which may have introduced a
significant crossover effect and bias
against PET. Third, patients in the
PET arm with prior testing had signif-
icantly better outcomes than those in:
1) the standard arm with other testing;
2) the standard arm without other test-
ing; and 3) the PET arm without prior
testing. All of which suggests that an
algorithm with PET after initial testing
might provide clinical benefits. Thus,
whereas randomization in PARR-2
was designed to reduce selection and
referral biases, the high nonadherence
rate and significant use of other testing
in the standard arm highlight the re-
markable challenges of this type of trial
n Medical Therapy
Nonviable
7.7
6.2
23.0%
   
2
 =1.43
p = 0.23
t Myocardial Viability Treated by
lity was noted with revascularization versus medi-
signiﬁcant difference in mortality between the
lman et al. (3).design. Other important findings in mPARR-2 were: 1) revascularization and
revascularization work-up rates differed
significantly relative to viability extent,
suggesting that PET had an important
impact on management decisions; and
2) PET-assisted management yielded a
significant mortality benefit in patients
without recent angiography, perhaps by
optimizing patient selection for revas-
cularization work-up and subsequent
decision making.
STICH—OVERALL TRIAL. The clinical
quipoise between surgical and nonsur-
ical management of ischemic LV sys-
olic dysfunction has led to the STICH
rial, to date, the largest RCT of
ABG versus medical therapy in
oderate-to-severe ischemic LV sys-
olic dysfunction (1). This rigorously
onducted trial randomized 1,212 pa-
ients to medical therapy versus medical
herapy plus CABG. By intention-to-
reat analysis, no significant difference
n the primary endpoint of all-cause
eath was observed between the 2 ran-
omized arms at a median follow-up of
6 months. However, whereas adher-
nce to randomization strategies was
easonably high, crossover occurred in
7% of patients assigned to medical
herapy and 9% of patients assigned to
ABG, potentially reducing the treat-
ent effect. When as-treated and per-
rotocol analyses were performed,
ighly significant differences in the pri-
ary outcome favoring CABG were
bserved (Fig. 2). Furthermore, com-
ared with those assigned to medical
herapy, patients assigned to CABG
ad significantly lower rates of second-
ry endpoints, including cardiovascular
nd combined all-cause death or hos-
italization for heart failure (HF).
Similar to other large RCT in the
ontemporary era, STICH randomized
very small proportion of eligible pa-
ients at 127 sites in 26 countries over 5
ears, averaging only 2 patients per site
er year. The outcome of the large
umber of screened patients who did
ot undergo randomization was not
eported. Suitable surgical candidateszatio
hou
orta
noay not have been randomized and
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553may have undergone operations,
whereas patients included in the RCT
may have been those in whom the
efficacy of revascularization was already
in doubt because they were less suit-
able, or perhaps even unsuitable, poten-
tially biasing against surgery. Thus,
STICH, though rigorous, still leaves
uncertainty regarding optimal manage-
ment and does not dispel the long-
standing notion that some patients
with moderate-to-severe ischemic LV
systolic dysfunction may derive benefit
from revascularization.
STICH—VIABILITY. A noteworthy sub-
study of STICH addressed the efficacy
of viability testing (2). This nonran-
domized viability substudy included
601 patients who underwent optional
viability testing by single-photon emis-
sion computed tomography (SPECT),
dobutamine echocardiography, or both,
and who were randomly assigned to
CABG (n  298) versus medical ther-
apy (n 303). In the 487 patients with
1.0
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Figure 2. Kaplan-Meier Estimates of Death From
Per-Protocol Basis
(A) Kaplan-Meier estimate of death from any cause
randomly assigned to medical therapy (MED) who
(CABG) during the ﬁrst year of follow-up and patie
demonstrated signiﬁcantly lower mortality rate with
cause on an as-treated basis. Analysis comparing p
went CABG either because of randomization or cro
strated signiﬁcantly lower mortality rate with CABG
CI  conﬁdence interval; HR  hazard ratio.evidence of viability, 244 patients wereassigned to CABG and 243 to medical
therapy. In the 114 patients without
viability, 54 were assigned to CABG
and 60 to medical therapy. At a median
follow-up of 5.1 years, several key find-
ings were noted. First, patients with
viable myocardium had lower overall
rates of the primary outcome of death
(hazard ratio: 0.64; p  0.003) than
patients without viable myocardium
did. However, after adjustment for
other significant baseline prognostic
variables in the multivariate model, vi-
ability status was no longer significantly
associated with death. Second, lower
rates of the secondary endpoints of
cardiovascular death (hazard ratio:
0.61; p  0.003), and a composite of
death or hospitalization for cardiovas-
cular causes (hazard ratio: 0.59; p 
0.001) were noted in patients with
myocardial viability than for patients
without viability. On multivariate anal-
ysis, the relationship between myocar-
dial viability and death from cardiovas-
592 516 464 412 297 146 74
620 548 509 482 355 182 97
MED
CABG
HR
0.70
95% CI
0.58-0.84
p
<0.001
10 2 3 4 5 6
Years from Randomization
B
y Cause on an As-Treated Basis or on a
a per-protocol basis. Analysis comparing patients
not crossover to coronary artery bypass graft
ssigned to CABG who actually underwent CABG
BG. (B) Kaplan-Meier estimate of death from any
ts treated with MED and patients who under-
er during the ﬁrst year of follow-up demon-
apted, with permission, from Velazquez et al. (1).cular causes was not significant,whereas the relationship between via-
bility and the composite of death or
hospitalization for cardiovascular
causes remained significant. Third,
there was no significant interaction be-
tween myocardial viability and study
group assignment to CABG or medical
therapy with respect to death, cardio-
vascular death, or the composite end-
point. However, there was a nonsignif-
icant trend suggesting greater benefit of
CABG in patients without viability
(Fig. 3). Fourth, analysis according to
treatment actually received showed no
interaction between viability status and
treatment with respect to primary and
secondary outcomes.
The STICH viability substudy raises
valid questions regarding the efficacy of
viability testing, but its strengths and
weaknesses should be examined before
generalizing results beyond the study
population. In addition to overall trial
limitations (Table 1), the STICH via-
bility substudy, like its observational
predecessors, did not mandate viability
testing or randomize according to via-
bility testing results. Rather, viability
testing was performed at the clinician’s
discretion in about one-half of eligible
patients. Moreover, significant differ-
ences in baseline characteristics be-
tween patients with and without viabil-
ity testing were present, including
differences in race, prior MI, percuta-
neous coronary intervention, proximal
left anterior descending coronary artery
stenosis, symptom status, medication
use, LV ejection fraction, and volumes.
The STICH investigators state that
they cannot exclude the possibility that
viability testing results could have in-
fluenced clinical decision making, be-
cause there was a nonsignificant trend
toward higher rates of CABG among
patients who underwent viability test-
ing on the day of randomization or on
the following day than there was
among those who underwent testing
before randomization. Thus, whereas
the substudy has the major strength of
being part of a rigorously conducted72
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554cautiously given these limitations. Fur-
thermore, although the viability tests
accepted in STICH are commonly
used in practice, these approaches have
lower sensitivity and negative predictive
value than PET or contrast-enhanced
cardiac magnetic resonance (7), which
might provide different results. The
thresholds for viability extent in
STICH also classified patients in a
binary fashion as either having or not
having substantial viability; however,
the viability extent required for func-
tional improvement after revasculariza-
tion has been a subject of longstanding
Without Viability 114 58 
   
With Viability 487 178 
   
Subgroup No. Deaths H
0.25
Figure 3. Interaction Between Viability Status an
In the STICH (Surgical Treatment for Ischemic He
cant interaction between viability status and trea
by intention-to-treat analysis. However, there wa
CABG was greater in patients without viability. Ada
ations as in Figure 2.
Table 1. Limitations of the STICH Viability Subst
Limitations of overall trial
Crossover in 17% of patients assigned to medica
Randomization of a very small proportion of elig
Average of only 2 patients per site per year at 1
Outcome of the large number of patients screen
Lack of randomization in viability substudy
Optional viability testing performed at clinician’s di
Only about one-half of eligible patients from the m
Signiﬁcant differences in baseline characteristics be
testing
Nonsigniﬁcant trend toward higher rates of CABG a
randomization or on the following day than a
Acceptable viability tests do not have highest sens
viable myocardium
Binary classiﬁcation of viability with controversial th
Stress-induced ischemia not consistently addressed
Revascularization not guided by the presence of vi
Small sample size of the group with nonviable myoCABG  coronary artery bypass graft; STICH  Surgical Treatmedebate, varying from 8% to 67% of the
LV (6). At the segmental level, a vari-
ety of relative and absolute tracer up-
take has also been used to define via-
bility by SPECT, again underscoring
the uncertainties surrounding the se-
lected viability thresholds in STICH.
Additional limitations of this definition
are that it does not distinguish between
normal myocardium versus hypocon-
tractile viable myocardium and does
not address whether stress-induced
ischemia was present, which could alter
outcomes with revascularization. Re-
vascularization was also not guided by
G
ter
Medical
Therapy
Better
0.70 0.53
(0.41 - 1.18)
0.86
(0.64 - 1.16)
ard Ratio (95% CI) p
50 1.0 2.0
reatment Assignment With Respect to Mortality
Failure) viability substudy, there was no signiﬁ-
nt assignment with respect to 5-year mortality
nonsigniﬁcant trend, suggesting the beneﬁt of
, with permission, from Bonow et al. (2). Abbrevi-
rapy and 9% of patients assigned to CABG
patients
ites in 26 countries over 5 years
ut not randomized not reported
tion
trial
en those with versus those without viability
ng patients with viability testing on the day of
g those who had testing before randomization
y or negative predictive value for identifying
olds for extent and uptake
viability testing
myocardium
diumnt for Ischemic Heart Failure.the presence of viable myocardium.
Lastly, the sample size of the group
with nonviable myocardium was rela-
tively small and might be underpow-
ered to detect significant differences in
the endpoints between the treatment
groups.
Until now, the concepts of myocar-
dial viability, the rationale for viability
testing, and the outcomes based on the
presence or absence of viability appear
logical and rational and are supported
by robust pathophysiological mecha-
nisms. It is, therefore, difficult to un-
derstand the seemingly counterintuitive
STICH findings of the slightly but
nonsignificantly better outcome of
CABG in patients without versus with
viability and the lack of significant in-
teraction between viability and study
group assignment with respect to out-
comes. A potential explanation is that
patients without viability in STICH
were a sicker group, as noted by signif-
icant differences in baseline character-
istics and, as described in prior trials,
the greatest benefit of revascularization
over medical therapy on survival is in
“sicker” patients.
Viability testing—conclusions. These
well-conducted contemporary studies
highlight the complexities of decision
making in this population but have
their limitations and do not provide
sufficient grounds for abandoning the
logical concept of viability. In this con-
text, it is also difficult to discount the
reasonable evidence from the last 2
decades and the rational pathophysio-
logical mechanisms. Limitations not-
withstanding, PARR-2 and STICH
have been excellent steps in the right
direction, and like many good trials,
have generated new questions regard-
ing patient selection for revasculariza-
tion, including the extent of viability,
the role of stress-induced ischemia, the
impact of LV remodeling, the interac-
tion of viability and scar, and the dura-
tion of myocardial dysfunction, along
with procedural issues of incomplete
revascularization and ischemic damage,CAB
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555age, prior revascularization, and patient
preference. The nuances of clinical de-
cision making in these patients and the
lingering clinical equipoise underscore
the continued need for prospective tri-
als of viability testing in patients with
moderate-to-severe ischemic LV sys-
tolic dysfunction.
Viability Testing May
Not Be Relevant in All
PatientsWith Ischemic
Left Ventricular
Dysfunction
Julio A. Panza, MD
I N PATIENTS WITH CAD, HF is the
result of LV systolic dysfunction and
accounts for about 60% to 70% of the
HF cases that develop in the United
States (10). The concept that chronic
LV dysfunction in the setting of CAD
is due to irreversibly damaged myocar-
dium was long ago outdated by the re-
alization that viable myocardium may
be present in areas with impaired con-
traction and that systolic function may
recover after revascularization.
Several uncontrolled studies have
shown, individually and in pooled
analyses, that patients with ischemic
cardiomyopathy and myocardial viabil-
ity show recovery of systolic function
and greater survival if revascularized,
compared with patients treated only
with medical therapy (3,7,8). Hence,
the concept has emerged that detection
of viable myocardium is a prerequisite
for the surgical treatment of ischemic
cardiomyopathy and, by extension, that
revascularization should be withheld in
the absence of viability.
Importantly, most of the findings
regarding myocardial viability have
been based on the results of small and
retrospective trials. Patients enrolled
in these studies were selected for via-
bility testing or revascularization in anunblinded fashion and, therefore,
these reports suffer from selection and
treatment biases. In addition, impor-
tant questions can be raised regarding
crucial methodological issues that af-
fect the practical application of infor-
mation regarding myocardial viability
for decision making. The available
studies show no consistency with re-
gard to the definition of viability.
Moreover, there is no consensus re-
garding whether viability is a dichoto-
mous or a continuous variable and
there is no definition of uniform qual-
itative or quantitative thresholds.
Prospective efforts to address the viability
question. Given the limitations of pub-
lished studies addressing this issue, un-
certainty remains as to how to apply
this information to clinical practice. To
date, 3 studies have prospectively ad-
dressed the viability question.
The PARR-2 trial was the first to
prospectively attempt to answer the
question of whether viability assess-
ment has a positive impact on the
outcome of patients with ischemic LV
dysfunction considered for revascular-
ization (4). In this clinical strategy
study, 430 patients were randomized
to undergo either imaging-assisted
(using PET assessment of viability) or
standard management regarding the
decision about revascularization. Im-
aging investigators analyzed the likeli-
hood of recovery of LV function us-
ing a pre-defined algorithm based on
a quantitative assessment of scar and
viable myocardium. The interpretation
and recommendations were sent to
the treating physicians who then de-
cided whether or not to perform re-
vascularization. The primary end-
point was the composite of death,
MI, and cardiac hospitalization within
12 months. The primary analysis
failed to show a significant difference
in favor of patients randomized to the
PET-guided arm (p  0.16). Unfor-
tunately, in about 25% of patients, theimaging-based recommendations were
not followed by the treating physi-
cians. When only patients who ad-
hered to the recommendations were
considered in a post hoc analysis,
there was a statistically significant
benefit for the PET-guided strategy
versus standard care (p  0.019). A
number of major limitations in the
design and conduct of the study have
been pointed out by others (11). Most
notably, the PARR-2 study was based
on the presumption that PET assess-
ment of viability correctly identifies
those patients who derive benefit
from revascularization (imaging-based
recommendation bias) and included in
its design different treating physicians’
perceptions regarding the potential
benefit of this intervention (clinical
decision bias). Hence, neither the in-
teraction between imaging results and
treatment nor the interaction between
treatment and outcome was free of
preconceived notions of benefit.
The HEART (Heart Failure Revascu-
larisation Trial) was an unblinded clin-
ical study that aimed to randomize
800 patients with symptomatic HF,
LV ejection fraction 35%, and evi-
dence of substantial myocardial viabil-
ity to either conservative management
or coronary angiography with the in-
tention of revascularization (12). Un-
fortunately, the study was stopped
early due to problems with recruiting
and funding. Of the 138 patients en-
rolled, 69 were randomized to a strat-
egy of revascularization, but only 45 ul-
timately underwent a procedure. There
were no differences in mortality by inten-
tion-to-treat, suggesting a lack of benefit
of revascularization therapy in patients
with viability. However, the trial was
clearly underpowered to address this
endpoint.
The STICH trial. The STICH trial is an
investigator-initiated, National Heart,
Lung, and Blood Institute–funded ran-
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556domized trial designed to test the hy-
pothesis that, in patients with HF, LV
ejection fraction 35%, and CAD
menable to revascularization, CABG
ombined with intensive medical ther-
py, when compared with medical
herapy alone, improves long-term
urvival.
STICH enrolled 1,212 patients who
ere randomized to medical therapy
alone or to medical therapy plus
CABG and who were followed until
at least 400 deaths occurred. Briefly,
after a median follow-up of 56
months, there was no statistically sig-
nificant difference between the 2
treatment arms in the primary out-
come of overall mortality (p  0.12).
Patients assigned to revascularization
with CABG had lower rates of car-
diovascular mortality (p  0.05) and
the composite endpoint of overall
mortality plus cardiovascular hospital-
ization (p  0.001) (1).
A total of 601 of the 1,212 (49.6%)
patients enrolled in STICH under-
went assessment of myocardial viabil-
ity with either SPECT or dobutamine
echocardiography. These patients, who
were randomly assigned to receive
medical therapy alone (303 patients)
or medical therapy plus CABG (298
patients), formed the basis of the
STICH myocardial viability substudy
(Fig. 4). Of the 601 patients, 487
were found to have substantial viabil-
ity using pre-specified criteria for each
imaging method based on the number
of viable myocardial segments. The
remaining 114 patients were consid-
ered as without viability. The number
of deaths among patients with viabil-
ity (178 or 37%) was significantly
lower than among patients without
viability (58 or 51%) (p  0.003).
However, this association was ren-
dered not significant in a multivari-
able model (p  0.21). There was no
significant interaction between viabil-
ity status and treatment for the pri-mary endpoint of overall mortality in
the intention-to-treat analysis (p 
0.53) or in the treatment-received
analysis (p  0.96). Similar results
were observed for the secondary end-
points of cardiovascular mortality and
the composite of overall mortality plus
cardiovascular hospitalization. The
lack of interaction between viability
status and treatment was also found
in a number of pre-specified analyses
that included assessment based on
median viability scores (to separate
the study population in 2 groups with
approximately equal numbers of pa-
tients) and assessment of viability as a
continuous variable. In addition, the
1,212 patients en
Revascularizatio
P = 0.53 for the interactio
and treatment assignme
243
patients
with
myocardial
viability
60
patients
without
myocardial
viability
95
deaths
33
deaths
601 patients inc
Myocardial Vi
303 patients randomized to
medical therapy alone
Figure 4. Flowchart of the STICH Myocardial Via
Approximately one-half of the patients included in
into the viability substudy. The allocation of treatm
that of the overall study population; hence, there
of a viability test and treatment assignment. The
sidered to have substantial amounts of viable my
dial viability was similar in both treatment arms
alone, and 82% of patients allocated to medical
between treatment assignment and viability stat
absence of viability and treatment with regard to
ations as in Figures 2 and 3.findings were similar when patientswho underwent SPECT or dobutamine
echocardiography were considered sepa-
rately (2). These findings contrast
sharply with those of retrospective stud-
ies and meta-analyses that also divided
patients into 2 treatment modalities
(medical therapy or revascularization)
and 2 viability subgroups (with and
without myocardial viability).
The STICH substudy is the first to
address this interaction in the context
of a clinical trial with random treatment
assignment and imaging analysis by
core laboratory investigators blinded
to all clinical information using pre-
specified criteria for assessment of via-
bility status. However, a number of
led in the STICH
ypothesis Trial
etween viability status
ith regard to mortality
244
patients
with
myocardial
viability
54
patients
without
myocardial
viability
83
deaths
25
deaths
d in the STICH
ity Substudy
298 patients randomized to
medical therapy plus CABG
y Substudy
STICH revascularization hypothesis were enrolled
by randomization in these patients was similar to
s no association bias between the performance
jority of patients (487 of 601 [81%]) were con-
rdium. The proportion of patients with myocar-
of patients allocated to medical therapy
apy plus CABG), indicating no association bias
here was no interaction between presence or
e primary outcome of overall mortality. Abbrevi-rol
n H
n b
nt w
lude
abil
bilit
the
ent
wa
ma
oca
(80%
ther
us. T
thimportant limitations must be consid-
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 5 5 0 – 8
Chareonthaitawee et al.
Viability Imaging in 2012
557ered, primarily the fact that the sub-
study only included one-half of the
patients enrolled in the STICH revas-
cularization hypothesis trial, and that
the performance of a viability test was
decided by the recruiting investigators
using 1 (or both) of 2 different imag-
ing methodologies. This latter limita-
tion could have resulted in imaging-
selection bias, such that the
proportion of patients with a substan-
tial amount of myocardial viability
was greater among those included in
the substudy than in those who did
not undergo viability testing. This
may explain the low proportion (19%)
of patients without viability included
in the substudy. Although this could
have negatively influenced the ability
to detect a differential effect of
CABG according to viability status,
there are no firm grounds to specu-
late that a diametrically opposed
finding could have resulted from in-
clusion of all STICH patients into
the substudy, given the striking lack
of interaction observed between via-
bility and treatment in all the analy-
ses performed.
Implications. None of the prospective
efforts to address the viability question
supports the use of viability testing as
the arbitrator in the decision-making
process regarding revascularization in
patients with ischemic cardiomyopa-
thy. This appears to contradict the
notion that revascularization of non-
viable segments lacks a reasonable
mechanistic underpinning. Further, it
is opposed to the postulate that im-
provement in systolic function with
revascularization (only possible in vi-
able segments) is associated with bet-
ter prognosis. Hence, clinicians are
now presented with the dilemma of
reconciling plausible biological con-
cepts already incorporated into prac-
tice with the opposing findings of
recent clinical trials.
Different possibilities may help ex-
plain these discrepancies. First, limita-tions in study design and completion
may have prevented the detection of a
true interaction between viability sta-
tus and the benefit of revasculariza-
tion. The ideal clinical trial—one in
which the results of viability testing
do not influence inclusion into the
study or treatment allocation—has yet
to be conducted, and likely never will
be given the findings of the STICH
trial. However, despite its limitations,
one must not overlook the fact that
the STICH substudy randomized 487
patients with substantial amounts of
viable myocardium to medical therapy
with or without revascularization, and
yet its results were far from even sug-
gesting a preferential benefit of
CABG in these patients compared
with those without viability. Second,
it is possible that the advances in
medical and device therapy have
markedly reduced the added benefit of
revascularization, such that it is diffi-
cult to demonstrate further improve-
ment in clinical outcomes. Third, the
benefit of CABG may not be related
to revascularization of viable segments
but rather to revascularization of po-
tentially ischemic segments. Further
exploration of this hypothesis using
the STICH trial database is currently
underway. Similarly, the critical infor-
mation may lie not in the presence
but rather in the absence of viability
using methods such as cardiac mag-
netic resonance that focus on the de-
tection of myocardial scarring. Finally,
one must consider that the greatest
benefit of CABG may be limited to
those patients with more advanced
forms of the disease, including those
with a relatively small amount of via-
ble myocardium.
Do the results of the STICH trial
suggest that testing for myocardial vi-
ability testing is fruitless and should
be abandoned? Perhaps not entirely,
but they certainly do not lend cre-dence to the widespread use of viabil-
ity results as a prerequisite for CABG
in patients with ischemic LV dysfunc-
tion. Patients with ischemic cardio-
myopathy constitute a heterogeneous
population with an extremely complex
condition in which multiple factors
play an important prognostic role. In
this context, it would be simplistic to
expect that a single feature (i.e., the
presence of viable myocardium) would
provide an unequivocal answer to a
critical question for all patients.
Contrary to the hopes of investiga-
tors and physicians involved in the
care of these patients, the findings of
prospective studies have not simpli-
fied the decision-making process re-
garding CABG in ischemic cardio-
myopathy. Instead, they are valuable
in that they demystify the emphasis
previously placed—without appropri-
ate evidence—in the significance of
myocardial viability. These results
once again underscore the importance
of testing a hypothesis in a prospec-
tive trial before adopting it as dogma.
In the clinical arena, these observa-
tions remind physicians to consider the
multiplicity of factors involved in the
decision-making process for patients
with complex medical conditions.
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